Document:

ViroPharma Board Compensation Policy

 Exhibit 10.10 
 ViroPharma Incorporated 
 Board Compensation Policy 

Members of the Board of Directors of ViroPharma Incorporated (the “Board”) that are non-executive officers of ViroPharma Incorporated (the
“Company”), and directors that are not affiliated with a person or entity that has been granted a contractual right to appoint a director to the Board (“Eligible Directors”), shall receive compensation in accordance with the
policy set forth below. Eligible Directors shall not be entitled to receive any other compensation for service on the Board. 
 Cash
Retainer Fees: 
 Effective January 1, 2011, the annual cash retainer fees for Eligible Directors shall be as follows: 

 

			
	Description	  	Annual Amount
		
	Annual Retainer	  	$40,000
		
	Additional Retainer for Chairman of the Board	  	$30,000
		
	Additional Retainer for Lead Independent
Directori	  	$10,000
		
	Committee Chair Retainer	  	Audit Committee: $20,000
		
		  	Compensation Committee: $10,000
		
		  	Nominating and Governance Committee: $5,000
		
	Committee Retainer	  	Audit Committee: $10,000
		
		  	Compensation Committee: $8,000
		
		  	Nominating and Governance Committee: $5,000

 In the event a
new Eligible Director is elected or appointed to the Board, such Eligible Director shall be eligible to receive as compensation for service as a member of the Board a pro-rated amount of the annual retainer based on the period from the date of
election or appointment through the end of the calendar year. 
 In addition, Eligible Directors shall also receive reimbursement for reasonable
travel expenses for each board and committee meeting that they attend. 

 Equity Award Grants: 
 Effective January 1, 2011, Eligible Directors shall receive equity awards as follows: 

Initial Equity Award Grant 
 Upon
his or her initial election to the Board, Eligible Directors shall receive a grant of (i) an option to purchase 12,500 shares of common stock, and (ii) 6,250 Restricted Stock Units (“RSUs”); each vesting in equal increments over three (3)
years. 
 Annual Equity Award Grant 
 Once each year Eligible Directors shall also receive a grant of (i) an option to purchase 15,000 shares of common stock and (ii) 4,500 RSUs; each vesting in full after one (1) year from the date of grant.

 In a director’s initial year of service, he or she will be entitled to receive (1) the Initial Equity Award Grant, and (2) a pro-rata
portion of the Annual Equity Award grant. 
 Each equity grant will be evidenced by, and subject to the terms and conditions of, an award
agreement in the form approved by the Board of Directors to evidence such type of grant pursuant to this policy and the Company’s Amended and Restated 2005 Equity Incentive Plan. 
 Taxes 
 Each Eligible Director is responsible for his/her own taxes, tax planning and
tax filings regarding any cash retainer amounts paid and any grant of an Initial Equity Award Grant or Annual Equity Award Grant to such Eligible Director by the Company, including, without limitation, any Section 83(b) election that such Eligible
Director may wish to file. The Company will not assume any liability or obligation regarding any tax filing (including Section 83(b) elections) even if the Eligible Director has requested, and the Company has agreed to prepare and/or file any such
filings with the appropriate tax authorities. 
 Administration; Amendment; Governing Law 

This policy shall be administered by the Compensation Committee of the Board. The Board may amend or terminate this policy at any time, provided, however,
that equity awards under this policy will cease without any action of the Compensation Committee or Board if the Plan expires and the Board does not designate a successor plan under which the equity awards are to be made. This policy shall be
administered and enforced according to the laws of the Commonwealth of Pennsylvania. 
  

 

	i	 The Chairman of the Board shall receive compensation only if such Chairman is an independent director as set forth in requirements of the Nasdaq Stock
Market.Second Amended and Restated Bulk Material Supply Agreement

 Exhibit 10.50 
 ***     INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED. 
 Second Amended and Restated
Bulk Material Supply Agreement 
 Parties 
 ViroPharma Incorporated, a Delaware corporation, with offices at 730 Stockton Drive, Exton, PA 19341, USA (“ViroPharma”); and 

Xellia Pharmaceuticals Inc., a Delaware corporation, with offices at 34121 N. Hwy 45, Suite 207, Grayslake, IL 60030, USA, the successor in interest
hereunder to Alpharma Inc. (“Xellia”). 
 Effective Date of this Second Amended and Restated Bulk Materials Supply
Agreement (this “Agreement”): January 1, 2011 (the “Effective Date”). 
 Signature Date of
this Second Amended and Restated Bulk Materials Supply Agreement: December 14, 2010. 
 Expiration Date (subject to termination
provisions): The term of this Agreement shall continue until December 31, 2015 (the “Initial Term”). Following the Initial Term, this Agreement shall automatically renew for a one (1) year period unless ViroPharma
delivers written notice to Xellia of its intention not to renew at least *** prior to the end of the Initial Term and, thereafter, this Agreement shall renew for consecutive periods of one (1) year (each a “Renewal
Term”) unless and until either party submits to the other party written notice of its intention not to renew at least *** prior to the end of any Renewal Term. 
 Background 
 ViroPharma is a corporation that develops and sells pharmaceutical products.

 Xellia is experienced in manufacturing certain active pharmaceutical ingredients. 
 ViroPharma and Alpharma, Inc., the predecessor-in-interest to Xellia, had entered into that certain Amendned and Restated Bulk Material Supply Agreement, effective as of April 5, 2006 (the
“Superseded Agreement”) which has governed purchases of Product by ViroPharma. 
 ViroPharma and Xellia have come to
certain understandings regarding their on-going supply relationship and wish to memorialize those understandings by amending and restating the Superseded Agreement and entering into this Second Amended and Restated Bulk Material Supply Agreement.

 The parties agree that the Amended and Restated Quality Agreement, a copy of which is attached hereto as Exhibit B (the “Quality
Agreement”) shall remain in full force and effect during the Initial Term and each Renewal Term. For the sake of clarity, the parties agree and acknowledge that Xellia, as successor-in-interest to Alpharma, is a party to the Quality
Agreement and all references to Alpharma in the Quality Agreement shall be deemed to be references to Xellia. 

 Therefore, ViroPharma and Xellia agree as follows: 
 Xellia and ViroPharma hereby amend and restate the Superseded Agreement in its entirety and replace it with this Agreement, effective as of the Effective Date. 

XELLIA’S RIGHTS AND OBLIGATIONS 
  

	1.	Xellia’s General Rights and Obligations 

 Xellia shall supply to ViroPharma certain of ViroPharma’s requirements for Product, subject to and in accordance with the terms and conditions of this Agreement, including the Product Specifications
(attached as Exhibit C - Product Specifications). 
  

	2.	Manufacture and Supply of Product 

 (a)
Xellia will manufacture Product at Xellia’s United States Food and Drug Administration (“FDA”) approved facilities in *** in accordance with cGMP, the Product Specifications and the Quality Agreement and Applicable Law.
ViroPharma shall be fully responsible for the safety and efficacy, and compliance with all Applicable Laws, in connection with the use (and the manner and method of use) of the Products in finished dosage form pharmaceutical products into which the
Products are introduced by ViroPharma, except to the extent that any safety or efficacy problem is related to the manufacture of the Product. 

(b) Xellia will notify ViroPharma of any changes, including but not limited to any change in the manufacturing process or Product specifications or
control methods which are likely to alter the identity, purity, quality, potency or stability of the Product and which require a regulatory filing with the FDA. Xellia will notify ViroPharma not less than ninety (90) days prior to
implementation of any such change so that ViroPharma will have reasonable time to allow ViroPharma to update applicable regulatory filings and evaluate the effect on its finished product prior to receiving Product which incorporates the change.
However, Xellia will not notify ViroPharma of any Annual Reportable Changes before implementation. In the event that ViroPharma does not agree to accept Products with changes proposed by Xellia pursuant to this subsection (b), ViroPharma shall
promptly notify Xellia in writing of that decision. The parties shall then attempt in good faith to resolve ViroPharma’s objections over a thirty (30) day period, failing which resolution ViroPharma shall have the right to terminate this
Agreement with *** written notice provided, however, that during this *** termination period ViroPharma shall have the right to terminate this Agreement immediately upon written notice if at any time during the *** termination period Xellia is
unable to continue to supply to ViroPharma Product manufactured in accordance with the manufacturing process or Product specifications or control methods, as applicable, which were effective before the change implemented by Xellia to which
ViroPharma did not agree. 

  
 2 of 31

	3.	Xellia’s Invoices 

 (a)
Timing. Xellia will submit invoices for Product upon shipment from the place of delivery set forth in Section 25. 
 (b)
Invoices. Invoices must state the product name, lot number(s), quantities, manufacturing site *** and date of shipment for each delivery. 
 (c) Currency. Invoices will be in United States dollars and payment will be in United States dollars. If the invoice’s United States dollar amounts are derived from currency other than United
States dollars, Xellia must state the amount of that currency and use the appropriate exchange rate, as published in the Wall Street Journal on the date of shipment from the place of delivery set forth in Section 25, to convert that currency to
United States dollars. 
  

	4.	Allocation of Supply 

 (a) During the
term of this Agreement, except as explicitly set forth in this Agreement, Xellia will (at Xellia’s discretion) supply Product from either the ***, provided, however, that at least *** percent***(***%) of the total aggregate quantity of Product
supplied from Xellia to ViroPharma during each calendar year shall be ***-Sourced Product, and at least *** percent***(***%) of the Product shall be ***. The parties acknowledge that the objective of the minimum supply percentages from each site
pursuant to the foregoing is to ensure continued qualification of Product manufactured at each site as source of Product. Xellia shall provide to ViroPharma written certification of the actual supply allocation on a quarterly basis. Further, upon
ViroPharma’s request the parties shall meet by telephone conference and/or in person to discuss the allocation. 
 (b) In the event of any
occurrence relating to the *** that affects or may affect Xellia’s ability to deliver Product in compliance with Section 4(a) above or any other terms of this Agreement, including any event of Force Majeure, Xellia shall:
(A) immediately notify and keep ViroPharma informed of such occurrence and Xellia’s management of such occurrence; and (B) notwithstanding Section 4(a) above increase its output of Product from the non-affected plant in order to
ensure continued supply of Product to ViroPharma in compliance with Xellia’s obligations under this Agreement. 
 (c) Xellia acknowledges
and agrees that if for any reason Xellia’s supply of Product at any time, including during an event of Force Majeure, is insufficient to meet its obligation to ViroPharma under this Agreement and to other customers under other agreements,
purchase orders or arrangements relating to the Product (a “Product Shortfall”) then during such Product Shortfall, Xellia agrees to allocate the available Product in a manner *** *** than to Xellia’s other ***customers,
provided that it is acknowledged that Xellia maintains safety stock of various products for certain customers and that if any safety stock of the Product is maintained by Xellia at the time of any Product Shortfall such safety stock will not be
taken into account when determining the allocation of Product. If Xellia’s inability to supply Product to ViroPharma affects only the ***, it is Xellia’s right and responsibility to supply Product to ViroPharma from the plant not affected
by the inability to supply Product in accordance with this Section 4(c) notwithstanding the requirement for minimum supply from each site pursuant to Section 4(a) above. 

  
 3 of 31

	5.	Debarment 

 Xellia represents and warrants
that (i) it is not and will not use and (ii) to the extent required under Applicable Law its Subcontractors are not and will not use, in any capacity, the services of any Person debarred under United States law (and if applicable under the
law of the country of manufacture) from participating in the development, or the application for approval of a drug product in connection with this Agreement. Xellia will require the same certification of Subcontractors, if applicable to this
Agreement. If at any time this representation and warranty is no longer accurate, Xellia shall promptly notify ViroPharma of such fact. 
  

	6.	Recalls 

 (a) In the event ViroPharma
should be required or should voluntarily decide to initiate a recall, withdrawal, or field correction of any ViroPharma pharmaceutical containing the Product, Xellia shall reasonably cooperate with ViroPharma concerning the necessity and nature of
such action if it is associated with the Product. 
 (b) In the event that Xellia independently believes that a recall, withdrawal, or field
correction of the ViroPharma pharmaceutical containing the Product may be necessary or appropriate due to reasons associated with the Product, Xellia shall notify ViroPharma and the parties shall fully cooperate with each other concerning the
necessity and nature of such action. 
 (c) In the event that any ViroPharma pharmaceutical containing the Product is recalled as a result of
(1) the Product supplied by Xellia not conforming to the warranties set forth in this Agreement, or (2) the negligent or intentionally wrongful act of Xellia or its representatives, then Xellia shall bear all of the out-of-pocket costs and
expenses directly related to such recall including, without limitation, expenses related to communications and meetings with all required regulatory agencies, expenses of replacement stock, the cost of notifying customers and costs associated with
shipment of recalled ViroPharma pharmaceuticals containing the Product from customers and shipment of an equal amount of replacement pharmaceuticals to those customers. In the event that any ViroPharma pharmaceutical containing the Product is
recalled for any other reason, then ViroPharma shall bear all of the costs and expenses of such recall, including without limitation expenses related to communications and meetings with all required regulatory agencies, expenses of replacement
stock, the cost of notifying customers and costs associated with shipment of recalled ViroPharma pharmaceuticals from customers and shipment of an equal amount of replacement ViroPharma pharmaceuticals to those customers. In the event that the
reason for any recall of ViroPharma pharmaceutical containing the Product hereunder is in part the responsibility of Xellia and in part the responsibility of ViroPharma, then the expenses shall be allocated ***. In the event either party decides to
proceed with a voluntary recall under subsections (a) or (b) above and the other party disagrees with the propriety of such voluntary recall, the cost sharing provisions of this subsection (c) shall only apply if a court of competent
jurisdiction holds that such recall was reasonable and proper. 

  
 4 of 31

	7.	Obligations at End of Term 

 (a) Upon
expiration, notice of termination or notice of cancellation of this Agreement, both parties will reasonably cooperate with each other to wind down and close this Agreement smoothly. Each party as the Receiving Party (as that term is defined in
Section 20) will also, at its sole expense and unless required otherwise by Applicable Law: (i) promptly effect the removal of Confidential Information (as such term is defined in Section 20) from its systems and files and those of
its Subcontractors (ii) deliver to the other party any of its property in the Receiving Party’s possession or control, and (iii) promptly deliver to the other party any Records of Confidential Information in its possession or control.

 (b) As an alternative to delivery of property or Records of Confidential Information, and if permitted by Applicable Law, each party may
direct the Receiving Party to destroy them or deliver them to another destination of the other party’s choosing. The exercise of this right must be in writing. 
  

	8.	Xellia’s Right to Cease Manufacturing 

If Xellia shall decide to discontinue manufacturing the Product, Xellia or its successor manufacturer may terminate this Agreement upon *** notice.

 VIROPHARMA’S RIGHTS AND OBLIGATIONS 

 

	9.	ViroPharma’s General Rights and Obligations 

 (a) Requirements. ViroPharma will purchase each calendar year no less than *** percent ***%) of its requirements for Product for the calendar year from Xellia, except for requirements for markets
where Product manufactured by Xellia has not been approved by the local marketing authority; provided that if Xellia is unable to meet the purchase orders of ViroPharma with respect to quantity ordered and time for delivery (assuming that such
purchase orders meet the terms of this Agreement), then ViroPharma may obtain *** from a third person, and such amount of Product shall be counted toward ViroPharma’s purchase requirements under this Section 9(a) and Section 14(a) as
specified in Clause 13 and 26. It is acknowledged that this Agreement does not prevent ViroPharma from establishing and qualifying third party suppliers of Product during the Term of this Agreement. For the purposes of clarity, the foregoing shall
not be understood to limit ViroPharma’s purchase requirements under Section 9(a) and 14(a) of this Agreement. 
 (b) Amount of
Payment. ViroPharma will pay Xellia the amounts described by and in accordance with this Agreement. 
 (c) Payment terms. Payment will be
due *** days after ViroPharma’s Accounts Payable Department receives an invoice that complies with the requirements in Section 3 of this Agreement, except that ViroPharma may withhold payment of any amount that it may reasonably dispute in
good faith until such dispute is resolved. Notwithstanding the foregoing provision, in the event of an assignment of this Agreement by ViroPharma, payment shall be made to Xellia by the assignee in advance of any shipment of Products until the
assignee is able to establish its creditworthiness to Xellia’s reasonable satisfaction. 

  
 5 of 31

	10.	Changes to Product Specifications 

ViroPharma, at its option from time to time, may request a change in the Product Specifications by notifying Xellia in writing. The parties will work
together in good faith to determine whether to implement the proposed change. As soon as possible, but in any event within *** days after the change request is received by Xellia, Xellia will notify ViroPharma of any adjustments in compensation or
delivery timing necessary to accommodate the changed Product Specifications. The revised Product Specifications will become applicable as of the date mutually agreed to by ViroPharma and Xellia, and all references thereafter to the “Product
Specifications” will refer to the Product Specifications as modified. The new Product Specifications will be attached hereto. Notwithstanding the above provisions, should Xellia and ViroPharma fail to reach agreement on the implementation of
any change in the Product Specifications, Xellia’s obligation to supply Products pursuant to the then presently effective Product Specifications shall remain unchanged and ViroPharma shall have the right to terminate this Agreement upon ***
months written notice. 
  

	11.	Intentionally Deleted 

  

	12.	ViroPharma’s Obligations at End of Term 

 In the event of any termination or cancellation of this Agreement before it expires, ViroPharma will be obligated to compensate Xellia only for work correctly performed prior to the termination or
cancellation including, without limitation, the purchase and payment for any Products then subject to a Purchase Order, as defined below in paragraph 14. 
 COMMERCIAL SUPPLY 
  

	13.	Forecasting 

 (a) During the term of this
Agreement, not less than *** days prior to the first day of each calendar quarter, ViroPharma shall provide Xellia with a rolling *** quarter forecast for its purchases of the Product (the “Forecast”). Each Forecast shall
represent ViroPharma’s best estimate at such time of its Product requirements from Xellia for such *** month period; provided, however, that the Forecasts (i) are for the convenience of Xellia only, (ii) shall not
constitute firm purchase or shipping orders, and (iii) shall not be binding upon, or create any obligation or liability with respect to, ViroPharma. Within *** days of ViroPharma’s submittal of each Forecast, Xellia will either confirm its
acceptance of the Forecast or submit a revised forecast, indicating delivery dates acceptable to Xellia. The parties agree that the purpose of this process is to accommodate both ViroPharma’s Product requirements and Xellia’s manufacturing
processes and business planning, and that they will discuss in good faith and reach agreement upon, a revised forecast. The first calendar quarter of such revised forecast, or the first calendar quarter of a Forecast accepted by Xellia without
revision, will be referred to herein as the “Accepted Forecast”. Once a Forecast is accepted for a given calendar quarter, ViroPharma may alter its forecasted Product requirements for any calendar quarter (except the ***
quarter for which a binding Purchase Order is required pursuant to Section 14) in a succeeding Forecast and Xellia may accept such new Forecast or respond with a proposed revised forecast, which will be discussed and agreed to between the
parties using the process described above (which shall thereupon become the new “Accepted Forecast”). 

  
 6 of 31

 (b) In the event that the parties are unable to agree on a revised forecast, and Xellia in good faith
indicates that it cannot meet the relevant Forecast proposed by ViroPharma, the parties agree to refer the matter to their respective senior managements. If Xellia is unable to supply ViroPharma’s requirements for Product for any calendar
quarter as set forth in a Forecast, then notwithstanding the requirements of Section 9(a) above, (a) ViroPharma shall be permitted to purchase from a third party an amount of Product equal to*** as reflected in such Forecast less the
amount of Product that Xellia indicates ***, and (b) such amount of Product shall be counted toward ViroPharma’s purchase requirements under Section 9(a) and Section 14(a) of this Agreement. 

 

	14.	Orders 

 (a) During the term of this
Agreement not less than *** days prior to the first day of each calendar month in which a delivery is required, ViroPharma will provide Xellia with a binding purchase order which cannot be cancelled or changed without the written consent of Xellia,
except as permitted by Section 26(c) (Late or Non-Delivery) setting forth the quantities of Product ordered for ***, the delivery dates for such quantities, shipping instructions, and the locations to which such quantities shall be delivered
(the “Purchase Order”). The quantities indicated in a Purchase Order will be for no less than ***percent***%) on a minimum-take-or-pay basis (the “Minimum Order”), and no more than ***percent***%) (the
“Maximum Order”), of the Accepted Forecast for that calendar month. For the purpose of clarity, Xellia will accept each Purchase Order that is submitted in accordance with the terms of this Agreement provided that quantities
of Product set forth in the Purchase Order that exceed the Maximim Order will only be part of the Purchase Order to the extent provided in the following sentence. Xellia will use ***, consistent with its commitments to other customers, to supply
Product in excess of the Maximum Order, but shall not be obligated to do so. 
 (b) Within *** days after receipt of each Purchase Order, Xellia
shall confirm the delivery dates during such calendar month, such delivery date not to exceed *** days after the date specified in the Purchase Order. Xellia shall promptly notify ViroPharma of any delay in delivery dates and plant shutdown
schedules; provided that any such notifications of any delays or shutdowns shall not excuse Xellia of any of its obligations under this Agreement and ViroPharma’s receipt of such notifications with or without response thereto shall not, in the
absence of an explicit written waiver, constitute a waiver of any of ViroPharma’s rights hereunder. 
 (c) Any terms and conditions
contained in a Purchase Order or any confirmation or other document or instrument that conflict with the terms and conditions of this Agreement shall have no force or effect. 

 

	15.	Shipping 

 Shipping instructions and terms
shall be as set forth on Exhibit E - Shipping. 

  
 7 of 31

	16.	Records 

 During the term of this
Agreement and for three (3) years after its expiration or termination, Xellia will maintain production batch records and batch release documentation for the Product and ViroPharma will maintain such records and documentation for the products
manufactured by ViroPharma that include the Product. 
  

	17.	Pricing 

 (a) The purchase price for
Product supplied under this Agreement after the Effective Date through the termination or expiration of this Agreement shall be ***dollars ($*** per KgA, subject to any adjustments required under Section 17(c) (the “Purchase
Price”). For the sake of sake of clarity, the Purchase Price shall not *** during the term of this Agreement. 
 (b) The Purchase
Price will be Xellia’s total compensation for full performance of all its obligations under this Agreement (whether performed by Xellia or any of its Subcontractors), including (but not limited to) all labor, materials, expenses, overhead,
taxes and profit as well as shipping, customs, duties until the agreed place of delivery, as described in Section 25. 
 (c)
Notwithstanding Section 17(a) above, as from the Effective Date Xellia shall not invoice ViroPharma for a *** *** for the Product than that paid for the Product by*** provided that Xellia has ***that such *** ***are purchasing the ***for use in
a ***that is the ***with the ***for sale in the ***. If, at any time after the Effective Date Xellia should sell the Product to *** at a ***that is *** the ***and provided that Xellia has ***that such *** are purchasing the ***for use in ***that are
the ***or ***with the ***for sale in the ***, Xellia shall promptly notify ViroPharma and ViroPharma shall be entitled to receive ***the ***of such ***for the *** of the *** of this Agreement. Upon the written request of ViroPharma, Xellia agrees
that an officer of Xellia shall certify in writing to ViroPharma that Xellia is in compliance with this Section 17(c). 
  

	18.	Contacts 

 ViroPharma Contacts

  

					
	 	  	 Person primarily responsible for
accepting Product (may
be changed
anytime by ViroPharma).
	  	 Person primarily responsible for this
contractual
relationship (may be changed
anytime by ViroPharma).

			
	Name	  	***	  	***
			
	Position	  	Associate Director	  	Director
			
	Mailing Address	  	 730 Stockton Drive
 Exton,
PA 19341
	  	 730 Stockton Drive
 Exton,
PA 19341

			
	Telephone	  	***	  	***
			
	Facsimile	  	***	  	***
			
	E-mail	  	***	  	***

  
 8 of 31

 Xellia Contacts 
  

					
	 	  	 Person primarily responsible for
furnishing Product (may
be changed
anytime by Xellia).
	  	 Person primarily responsible for this
contractual
relationship (may be changed
anytime by Xellia).

			
	Name	  	***	  	***
			
	Position	  	Manager, Global Technical Support, API	  	Director of US Sales
			
	Mailing Address	  	 Xellia Pharmaceuticals ApS

Dalslandsgade 11
 P.O. Box 1736

2300 Copenhagen S, Denmark
	  	 Xellia Pharmaceuticals, Inc.

34121 N. Hwy 45, Suite 207
 Grayslake, IL
60030
 USA

			
	Telephone	  	***	  	***
			
	Facsimile	  	***	  	***
			
	E-mail	  	***	  	***

 INFORMATION AND PROPERTY RIGHTS AND
OBLIGATIONS 
  

	19.	Intellectual Property Rights 

 (a) Xellia
reserves all rights (other than the license granted by this Section 19) to Xellia’s Intellectual Capital, if any, that is incorporated into the Product. Xellia grants to ViroPharma, its Affiliates, and their respective
successors and permitted assigns a non-exclusive, world-wide, royalty-free license to such Xellia’s Intellectual Capital sufficient to allow full lawful use of the Products for the manufacture of ViroPharma’s finished product. 

(b) Product supplied by Xellia under the Agreement will be used by ViroPharma only for the purpose of manufacturing ViroPharma’s
finished products VANCOCIN® or any generic equivalent (the “Finished Dosage Form”) for
sale in the United States, which Finished Dossage Form will be distributed and sold to third parties, either by ViroPharma itself, its Affiliates or by third party contract manufacturers and distributors manufacturing and distributing
ViroPharma’s finished products on behalf of ViroPharma. ViroPharma warrants and undertakes not to use the Product for any other purpose whatsoever and not to resell the Product to any third party until such time as the Product has been
incorporated in ViroPharma’s Finished Dosage Form. 

  
 9 of 31

	20.	Confidentiality 

 (a) Because of this
Agreement, Xellia may have access to ViroPharma’s Confidential Information, and ViroPharma may have access to Xellia’s Confidential Information (for the purposes of this Section 20, ViroPharma’s Confidential Information and
Xellia’s Confidential Information shall collectively be referred to as “Confidential Information”). Both parties will hold Confidential Information of the other party (“Disclosing Party”) in
strict confidence and will not use it for purposes other than those set forth in this Agreement. The party receiving the Confidential Information (the “Receiving Party”) will reveal Confidential Information only to those
Employees and Employees of Subcontractors who need to know the information to perform under this Agreement and who have executed a confidentiality and non-use undertaking agreement consistent with this Section. The Receiving Party will inform its
Employees who have access to Confidential Information of its confidential nature. The Receiving Party is responsible for any unauthorized use or disclosure of Confidential Information by its Employees, its Subcontractors, or its Subcontractors’
Employees. 
 (b) Confidential Information shall not include any information which the Receiving Party can show: (a) was in the public
domain prior to disclosure to the Receiving Party, or which thereafter came into the public domain without the Fault, or without the breach of any confidentiality obligation by the Receiving Party; or (b) was known by the Receiving Party prior
to disclosure as shown by competent evidence; or (c) was disclosed to the Receiving Party by a third party not in violation of any obligations of confidentiality to the Disclosing Party; or (d) is independently developed by employees of
the Receiving Party who have not had access to any Confidential Information of the Disclosing Party; or (e) is required to be disclosed by Applicable Law, but only if the Receiving Party gives the Disclosing Party prior written notice in order
to allow the Disclosing Party a reasonable opportunity to prevent disclosure or to seek entry of a protective order; or (f) was approved for release by written authorization of the Disclosing Party. 

(c) Nothing in this Section gives the Receiving Party any right or license in any patent, trade secret, copyright, trademark or other Intellectual
Property of the Disclosing Party, other than to use Confidential Information for purposes of this Agreement. 
 (d) Upon written instruction
from the Disclosing Party, and consistent with requirements of Applicable Law, the Receiving Party will promptly effect the removal of all copies and instances of Confidential Information from its systems and files and those of its Subcontractors
and deliver to the Disclosing Party or otherwise dispose of all Records containing Confidential Information in the Receiving Party’s possession or control. 
 (e) The parties’ obligations under this Section shall remain in effect during the term of this Agreement and shall continue for ten (10) years thereafter. 

 

	21.	Audit Record Creation and Retention 

 (a)
At its own expense, Xellia will create and maintain all Records required by this Agreement and by Applicable Law that relates to this Agreement and to Xellia’s performance under this Agreement. Such Records shall also be sufficient to:
(A) demonstrate that any and all amounts invoiced to ViroPharma under this Agreement are accurate and proper in both kind and amount; (B) demonstrate the accuracy of any 

  
 10 of 31

 
representations or reports submitted to ViroPharma under this Agreement; and (C) enable ViroPharma to comply with Applicable Laws and other legal obligations, to the extent that Xellia has
or reasonably should have knowledge of those Applicable Laws and other legal obligations. 
 (b) In creating and maintaining Records, each party
will employ standards and practices that are no less rigorous than those employed by prudent, well managed enterprises within their respective countries of domicile that provide types of products similar to those Xellia provides under this
Agreement, and to those that ViroPharma manufactures with those Xellia or similar types of products. Each party will maintain all of the Records listed above for the longest of the following retention periods that applies: (i) any period
prescribed by Applicable Law or stated expressly in this Agreement in another section, (ii) for Records related to invoices, for three (3) years after payment of the invoice by ViroPharma, (iii) for Records related to reports
submitted to ViroPharma, for three (3) years after the report is submitted, and (iv) for all Records not addressed by one of the above, for three (3) years after the term of this Agreement. 

Access to Records and Facilities 

(c) Subject to Section 20 (Confidentiality) and to subsection (d) of this Section, each party, as the Audited Party, will allow the other party,
as the Auditing Party, to inspect Records the Audited Party is required to create or maintain under this Agreement for the purposes of evaluating and verifying: (i) compliance with the requirements of this Agreement, (ii) compliance with
Applicable Law related to this Agreement or to the Audited Party’s performance under this Agreement, (iii) in the case of Xellia, the accuracy and propriety of any invoice submitted to ViroPharma, and (iv) the accuracy of any
representations or reports submitted to the Auditing Party. 
 (d) During the Audited Party’s regular business hours, and upon *** advance
written notice, the Auditing Party may enter and inspect any premises where Records are maintained or Products are manufactured as the Auditing Party deems necessary to accomplish the evaluations and verifications described in subsection (c) of
this Section. The Audited Party will cooperate with the Auditing Party and provide reasonable assistance to the Auditing Party to facilitate the evaluation and inspection, and the Auditing Party will reasonably cooperate with the Audited Party to
mitigate disruption to the Audited Party’s operations. In the event that Records are maintained, Products are manufactured, or the Auditing Party’s Property is kept at premises that the Audited Party does not control, the Audited Party
will secure rights of entry and inspection sufficient to allow the Auditing Party to exercise its rights under this Section. The Auditing Party, its Employees or its designees may exercise the Auditing Party’s rights of entry and inspection
under this Section; provided however that, unless prohibited by Applicable Law, anyone conducting or participating in such an inspection shall be required to execute a confidentiality agreement consistent with the confidentiality
provisions of this Agreement. Examples of Persons that the Auditing Party may designate include its independent auditors and representatives of Government Authorities having jurisdiction over the Audited Party or its activities related to this
Agreement. 

  
 11 of 31

 (e) Quality Audit Findings. Xellia agrees to cooperate with ViroPharma and to take such other actions
as may be reasonably necessary to carry out the purpose and intent of this Agreement with respect to manufacturing quality and capability, including without limitation, developing action plans to address any technical deficiencies noticed by
ViroPharma and agreed to by Xellia in a timely manner. 
 (f) For Records generated by Electronic databases, spreadsheets, programs or the like,
the Auditing Party’s rights to access and inspection under this Section shall extend to the database, spreadsheet or program that generated the Record as well as the Record itself. 
 Audit Expenses 
 (g) The Auditing Party will pay its own expenses for any inspection
of the Records on Audited Party’s premises. 
 Other provisions 
 (h) Records required by this Section may also fall within the definition of legal work product or Xellia’s Intellectual Capital. The property rights to such Records are established elsewhere in this
Agreement, not this Section. The Records may contain ViroPharma’s Confidential Information, in which case Xellia must satisfy the obligations under the Confidentiality section, in addition to the obligations of this Section. 

(i) Each party’s obligations to maintain Records under this Section are extinguished to the extent that such party properly satisfies an obligation
elsewhere in this Agreement to dispose of such Records or to deliver such Records to the other party or otherwise properly disposes of them in accordance with other provisions of this Agreement. 

 

	22.	Publicity and Nondisclosure 

 (a) Neither
party will disclose any information about this Agreement, including its existence, nor will it use the name of the other party, such party’s employees or any product of such other party in any press release, advertisement or materials
distributed to prospective or existing customers, annual reports or any other public disclosure, except with such other party’s prior written consent or as required by Applicable Law. To the extent allowed by Applicable Law, if either party
desires to make a public announcement, such party will provide copies of any proposed disclosure for prior review and comment by the other party’s external corporate communications (public relations) department no less than ten (10) days
prior to disclosure. Under no circumstances will either party use the other party’s logo or represent, directly or indirectly, that any product provided by such party has been approved, recommended, certified or endorsed by such other party.

 (b) Any consent given by one party under this Section is revocable by written notice to the other party. 

(c) Notwithstanding anything in this Section 22 and Section 20 to the contrary, ViroPharma may, without the written consent of Xellia, make
mandatory filings or disclosures to the Securities and Exchange Commission required by applicable law that discuss the subject matter of this Agreement or any exhibit or attachment hereto (including without limitation, filing this Agreement and any
exhibit or attachment), provided that ViroPharma shall consult with Xellia before making any such disclosure or filing with reference to Xellia. 

  
 12 of 31

 REPRESENTATIONS AND WARRANTIES 

 

	23.	Xellia’s Representations and Warranties 

 Xellia represents and warrants that: 
  

	(a)	Xellia is duly organized and in good standing under the laws of the jurisdiction of its formation, and any authorization necessary for making and performing under this
Agreement have been given. 

  

	(b)	The making and performance of this Agreement do not conflict with Xellia’s governing documents or any contractual obligation to another. 

 

	(c)	Xellia’s performance under this Agreement (including the manufacture of Product and Xellia’s employment practices) complies with all Applicable Law.

  

	(d)	All Product (whether manufactured at the ***or ***) supplied by Xellia under this Agreement is or was and shall be manufactured in accordance with the Product
Specifications, cGMP, the Quality Agreement and all other Applicable Laws. 

  

	(e)	All Product (whether manufactured at the ***or ***) supplied by Xellia under this Agreement will conform to the Product Specifications. 

 

	(f)	Xellia has obtained all permits, licenses and other authorizations which are required under Applicable Law to manufacture the Product at the ***and***. Xellia is in
compliance, and during the term of this Agreement will take all actions necessary to comply, with all terms and conditions of any and all required permits, licenses and authorizations applicable to the manufacture and supply of Product. No Product
delivered to ViroPharma pursuant to this Agreement will be manufactured or processed in any equipment that has been used to process animal or human tissue. 

 

	(g)	All Products are and shall be at the time of delivery free from defects in material and workmanship. 

 

	(h)	The Products are shall be at the time of delivery free from all liens, Claims and encumbrances. 

 

	(i)	The manufacture, sale or use of the Products within *** and *** does not infringe any rights (including trademark rights, copyrights, patents, trade secrets, or
contractual rights) of any other Person, and any use thereof by ViroPharma or its successors consistent with this Agreement does not infringe such right; provided that such warranty does not extend to the form or function of the finished product
into which ViroPharma or its successors may incorporate the Products. This representation and warranty does not apply to infringement arising solely from ViroPharma’s or its successor’s use of the Product in a manner that is contrary to
Xellia’s recommendations, or in combination with other materials. 

  

	(j)	 EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH ABOVE IN THIS SECTION, XELLIA MAKES NO OTHER REPRESENTATION, GUARANTEE OR WARRANTY,
EXPRESS OR IMPLIED, OF ANY KIND OR NATURE AND, IN PARTICULAR AND WITHOUT LIMITATION, XELLIA EXPRESSLY DISCLAIMS ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR

  
 13 of 31

	 	 
FITNESS FOR A PARTICULAR USE OR PURPOSE WITH RESPECT TO THE PRODUCT SUPPLIED HEREUNDER, WHETHER USED SINGLY OR IN COMBINATION WITH OTHER SUBSTANCES OR IN ANY PROCESS OR OTHERWISE.

  

	24.	ViroPharma’s Representations and Warranties 

 ViroPharma represents and warrants that: 
  

	(a)	It is duly organized and in good standing under the laws of the jurisdiction of its formation, and any authorizations necessary for making and performing this Agreement
have been given. 

  

	(b)	The making and performance of this Agreement do not conflict with ViroPharma’s governing documents or and contractual obligation to another.

 RISK ALLOCATION 
  

	25.	Delivery and Risk of Loss 

 All Product
(whether manufactured at the ***or ***) will be delivered by Xellia ***. Title and risk of loss shall pass to ViroPharma ***. 
  

	26.	Breach and Remedies 

 (a) Remedies
cumulative. Except to the extent that remedies are expressly limited in this Agreement, each party is entitled to all the remedies available to it in law and in equity. The parties do not intend the identification of a particular remedy to limit
a party to that remedy unless the language clearly states that the remedy is the sole or exclusive remedy. 
 (b) Termination for material
breach or bankruptcy. This Agreement may be terminated immediately upon written notice by either party hereto, if: (1) the other party fails to remedy a material breach of this Agreement within ninety (90) days of written notice of
such breach; or (2) the other party shall file a petition for bankruptcy, shall be adjudicated bankrupt, shall take advantage of the insolvency laws of any state, territory or country, or shall have a receiver, trustee, or other court officer
appointed for its property. 
 (c) Late or Non-delivery of Product. In the event that Xellia fails to deliver Product on or before the
delivery date specified in the applicable Purchase Order, ViroPharma shall notify Xellia of such delay and Xellia shall provide ViroPharma with the precise date of arrival for the shipment. If ViroPharma cannot accept the new date specified for
delivery by Xellia, or if the shipment fails to arrive within *** days after the newly specified date to which ViroPharma has agreed, then ViroPharma may cancel all or a portion of the affected order without liability to Xellia. The quantities so
cancelled will be credited against ViroPharma’s purchase requirements under Section 9(a) and 14(a) of this Agreement. In addition, provided that the reason for the delay is caused by Xellia, Xellia will reimburse ViroPharma for the
difference between ViroPharma’s contract price with Xellia under this Agreement and the actual cost of any cover product purchased by ViroPharma upon Xellia’s failure to supply provided that Xellia shall not, in any event, owe ViroPharma a
payment under this subsection (c) which exceeds ***% of the 

  
 14 of 31

 
purchase price of all cancelled orders if such Products had been timely delivered hereunder. The remedies set forth in this subparagraph 26(c) shall be ViroPharma’s sole and exclusive remedy
in respect of late or non-delivery of Product except, if applicable, the remedies set forth in Sections 26(b) and (f). 
 (d) Non-conforming
Product. ViroPharma reserves the right to reject Product that does not conform to the Product Specifications. ViroPharma will provide written notice that Product has been rejected within *** days of receipt of the Product, or within *** days of
discovery of the non-conformity, should it not be evident upon reasonable inspection at the time of delivery. Within *** days after receipt of such rejection, Xellia will have the right to inspect such Product at ViroPharma’s facility and,
whether or not it conducts such an inspection, Xellia shall determine within *** days after receipt of ViroPharma’s written notice whether the Product at issue is non-conforming, following which determination: 

(1) If Xellia has determined that the rejected Product is non-conforming, it shall accept return of the Product and, at Xellia’s
discretion, either (1) replace the non-conforming Product with new Product meeting the Product Specifications as quickly as possible, or (2) refund the purchase price paid by ViroPharma and ViroPharma’s shipping costs, within *** days
after receipt of ViroPharma’s rejection notice. If Xellia chooses not to so replace the non-conforming Product, ViroPharma shall have the right to obtain substitute product from another supplier. If ViroPharma exercises that right, it shall so
notify Xellia and shall provide Xellia with the invoice covering the replacement product. Provided that the reason that the Product was non-conforming is caused by Xellia, upon receipt of which invoice, Xellia will reimburse ViroPharma for the
difference between ViroPharma’s contract price with Xellia under this Agreement and the actual cost of the cover product purchased by ViroPharma to replace the non-conforming Product provided that Xellia shall not, in any event, owe ViroPharma
a payment under this subsection (d)(1) which exceeds *** percent (***%) of the contract price under this Agreement for the returned non-conforming Product. Any non-conforming Product for which Xellia elects to issue a refund will be credited against
all of ViroPharma’s purchase requirements under Section 9(a) and 14(a) of this Agreement. 
 (2) If Xellia has
determined that the rejected Product conforms to the Product Specifications and if the parties, after good faith discussion for a period of *** days between their senior managements, are unable to resolve the issue of conformity, then the issue
shall be referred to an independent third party expert (“Mediator”) agreeable to both parties for final resolution. If the parties are unable to agree on a Mediator, then each party shall appoint an expert, and the two
experts shall jointly appoint a Mediator to finally resolve the issue of conformity. Pending the Mediator’s award, ViroPharma shall have the rights set forth in the preceding subsection 26(d)(1), subject to reimbursement of Xellia if the
Mediator determines that the rejected Product met Product Specifications. 
 (3) Regardless whether or not Xellia agrees that
the rejected Product is non-conforming, if the rejection of the Product results in an urgent need for replacement Product for ViroPharma, ViroPharma shall be entitled to request that Xellia supplies an additional quantity of Product substantially
identical to the Product rejected by ViroPharma, such request to include indication of the desired delivery date. Xellia will use commercially reasonable efforts to supply such quantity of Product to ViroPharma within the requested delivery date,
but shall not be obligated to do so. The Product shall be supplied in accordance with the terms and conditions, including pricing and delivery, of this Agreement. 

  
 15 of 31

 The remedies set forth in this subparagraph 26(d) shall be ViroPharma’s sole remedies for Product that
ViroPharma has rejected as non-conforming, except, if applicable, the remedies set forth in Sections 26(b) and (f). 
 (e) Equitable
relief. Both parties acknowledge that, due to the nature of their respective businesses, monetary damages are inadequate to protect them from any threatened or actual breach of their respective duty to protect the Receiving Party’s
Confidential Information and that any breach will cause irreparable harm to the Receiving Party. Accordingly, both parties agree that the Receiving Party shall be entitled to an injunction restraining any breach or threatened breach of
Section 20 (Confidentiality) above without having to prove the inadequacy of monetary damages or irreparable harm. 
 (f) Remedies For
Certain Breaches. For the purpose of this Section 26(f), a “Triggering Event” shall mean if Xellia fails to deliver Product on or before the delivery date specified in the applicable Purchase Order or Product delivered to
ViroPharma by Xellia fails to meet the quality requirements and any other requirements set forth in this Agreement, provided that any such failure is not caused by Force Majeure, and in all instances whether or not the parties agree that such
Triggering Event is a material breach of the Agreement or, with the passage of time may become a material breach of the Agreement. In the event that a Triggering Event occurs three (3) or more times in the trailing six (6) month period,
then ViroPharma shall have the right, upon delivery of written notice to Xellia, to purchase Product from third parties notwithstanding ViroPharma’s purchase requirements under Section 9(a) and 14(a) of this Agreement, with all amounts
purchased from such third parties credited towards amounts that ViroPharma is obligated to purchase from Xellia under under Section 9(a) and 14(a) of this Agreement, until such time that Xellia has addressed such issues. Xellia will be deemed
to have addressed the issues at the latest at such time that during the trailing six months period no Triggering Event has occurred. 
  

	27.	Insurance 

 Each party will maintain all
the insurance policies listed in the attached Exhibit D - Insurance with insurers reasonably acceptable to the other party with limits no less than those in the Exhibit. The policies (whether based on occurrence or Claims made) will
cover all material occurrences or accidents arising under this Agreement which are subject to a standard Commercial General Liability policy. Immediately after this Agreement is fully executed, and on the annual renewal date of such policies
thereafter, each party will furnish the other party a certificate of insurance evidencing such coverage, and stating that the insurers reflected in such certificate will (at a minimum) endeavor to notify the other party at least *** days in advance
of cancellation. All policies will name the other party as an additional insured and will contain a waiver of subrogation if favor of the other party. The policies will cover Claims arising from the acts or omissions of the respective insureds and
anyone for whose acts or omissions they 

  
 16 of 31

 
may be liable. In addition to the foregoing requirements, in the event of an assignment of this Agreement by ViroPharma, the assignee shall provide Xellia, by the end of each calendar quarter,
with an updated certificate of insurance evidencing all such coverage and information. 
  

	28.	Indemnification 

 (a) Indemnification
by Xellia. Xellia agrees to indemnify, defend and hold harmless ViroPharma, its distributors, affiliates and their respective officers, directors, employees, and agents against any and all (i) third-party Claims, including Claims made
against ViroPharma by any of its distributors, and Claims made by Xellia’s Subcontractors and (ii) Losses incurred by any of them, to the extent such Claims and Losses arise out of any non-compliance with the Product Specifications
attached as Exhibit C - Product Specifications, or out of any breach of a representation, obligation, warranty or covenant hereunder by Xellia or any negligent or intentionally wrongful act or omission by Xellia, in connection with the
manufacture or delivery of the Product. 
 (b) Indemnification by ViroPharma. ViroPharma agrees to indemnify, defend and hold harmless
Xellia, its affiliates and their respective officers, directors, employees, and agents against any and all (i) third-party Claims, and (ii) Losses incurred by any of them to the extent such Claims and Losses arise out of any breach of any
representation, obligation, warranty or covenant hereunder by ViroPharma, or out of any negligent or intentionally wrongful act or omission by ViroPharma or, except to the extent covered by Section 28(a) (Indemnification by Xellia) above, in
connection with the production, marketing or sale of the finished dosage form of the Product. 
 (c) Third Party Claims. If either party,
including its distributors, affiliates or their respective officers, directors, employees, servants or agents (in each case an “Indemnitee”), receives any written Claim which such Indemnitee believes is the
subject of indemnity hereunder by the other party hereto (an “Indemnitor”), the Indemnitee shall promptly give notice thereof to the Indemnitor, provided that the failure to give timely notice to the Indemnitor
as contemplated hereby shall not release the Indemnitor from any liability to the Indemnitee unless the Indemnitor demonstrates that the defense of such Claim is prejudiced by such failure (and, in the event of such late notice, the Indemnitor is
only responsible for costs incurred after the notice is provided and the Indemnitee is responsible for any increase in costs related to its late notice). The Indemnitor shall have the right, by prompt notice to the Indemnitee, to assume the defense
of such Claim at its cost, with counsel reasonably satisfactory to the Indemnitee. If the Indemnitor does not so assume the defense of such Claim or, having done so, does not diligently pursue such defense, the Indemnitee may assume the defense,
with counsel of its choice, but at the cost of the Indemnitor. If the Indemnitor so assumes the defense, it shall have absolute control of the litigation; the Indemnitee may, nevertheless, participate therein through counsel of its choice and at its
cost. The party not assuming the defense of any such Claim shall render all reasonable assistance to the party assuming such defense, with all reasonable pre-approved out-of-pocket costs of such assistance (which shall not include any costs of time
spent) for the account of the Indemnitor. No such Claim shall be settled other than by the party defending the same, and then only with the consent of the other party, which consent shall not be unreasonably withheld; provided that the Indemnitee
shall have no obligation to consent to any settlement of any such Claim which imposes on the Indemnitee any liability or obligation which cannot be assumed or performed in full by the Indemnitor. 

  
 17 of 31

	29.	Force Majeure 

 Either party will be
excused from performing its obligations, other than its obligation to pay monies owed, under this Agreement to the extent that its performance is delayed or prevented by a Force Majeure. To be excused, the party claiming Force Majeure must promptly
notify the other party and exercise due diligence to avoid, remove or overcome the Force Majeure, except as set forth below with respect to labor strikes. The following is a non-exclusive list of examples that may qualify as Force Majeure: fire,
explosion, power failure, labor strikes (whether or not the demands of the employees involved are reasonable and within such party’s power to concede), acts of God, natural disasters, war, insurrection, civil strife, government acts and acts of
terrorism. This Agreement may be terminated by the party not asserting Force Majeure if an event of Force Majeure with respect to the asserting party shall have continued for *** days or is reasonably expected to continue for more than *** days.

 In the event that Xellia’s performance is excused because of Force Majeure, ViroPharma shall have the right, upon delivery of written
notice to Xellia, to purchase Product from third parties notwithstanding ViroPharma’s purchase requirements under Section 9(a) and 14(a) of this Agreement, with all amounts purchased from such third parties credited towards amounts that
ViroPharma is obligated to purchase from Xellia under Section 9(a) and 14(a) of this Agreement, until such time that Xellia’s performance is no longer excused because of Force Majeure. 

For the purposes of clarity, if the events and circumstances described in this Section only affect supply of Product from the ***, Xellia shall as soon
as possible arrange to supply Product to ViroPharma from the non-affected site in accordance with Section 4(c), and Xellia shall be excused from performing its obligations to supply Product to ViroPharma due to Force Majeure only for the period
of time reasonably required for Xellia to arrange the supply of the Product from the non-affected site. 
 GENERAL TERMS AND
CONDITIONS 
  

	30.	Independent Contractor 

 (a) In performing
its obligations under this Agreement, Xellia will be acting solely as an independent contractor and not in the capacity of an agent, partner, joint-venturer or in any other such capacity. Neither Xellia nor ViroPharma will have the authority to
bind, commit or incur any liability on behalf of the other party or to otherwise act in any way as agent or representative of the other party, except as specifically set forth herein. 
 (b) Neither Xellia, its Employees, and its Subcontractors nor its Subcontractors’ Employees will be considered employees of ViroPharma for any purpose. ViroPharma will not withhold any taxes, pay any
Social Security, pay unemployment compensation, or furnish worker’s compensation for any of them, and ViroPharma will not provide any employment benefits to any of them. 

  
 18 of 31

	31.	Succession, Assignment and Delegation 

(a) This Agreement will be binding upon and inure to the benefit of the parties to this Agreement and their respective heirs, executors, administrator,
successors and permitted assigns. 
 (b) Neither party will, in whole or in part, delegate obligations or duties of performance, or assign
rights under this Agreement (other than assignment of Xellia’s right to receive money) without (1) the other party’s prior written consent, which consent such other party may withhold or condition in its absolute discretion (except
that in case of assignment of the entire Agreement in connection with a sale, merger or consolidation involving all or substantially all of a Party’s business related to the Product, the other Party will not unreasonably withhold its consent;
and (2) the prior written agreement of the prospective assignee to be bound by the provisions of this Agreement. Any such attempted delegation or assignment without such written consent or without the assignee’s agreement will be void. For
the avoidance of doubt, a change of control of either Party shall not be considered attempted delegation or assignment of the Agreement by that Party. 
 (c) Should ViroPharma consent to Xellia’s use of a Subcontractor, Xellia will be fully responsible to ViroPharma for any portion of the performance of this Agreement by such Subcontractor, to the
same extent as if that performance was rendered directly by Xellia. Without limiting the generality of the foregoing, and in addition to the other rights and responsibilities set forth in this Agreement, the Parties acknowledge and agree that Xellia
is entitled to use ***, as a Subcontractor for certain services related to the manufacture at the ***. 
  

	32.	Severability 

 If a provision of this
Agreement is held to be unenforceable, the other provisions will remain in effect. If possible, the offending provision will be modified to the slightest degree necessary to make it enforceable, remaining as close as possible to the parties’
original intent for the provision. If not possible, the offending provision will be stricken. 
  

	33.	Contract Interpretation 

 (a) The meaning
of a provision of this Agreement will be considered in context with other provisions of the Agreement. 
 (b) The following principles apply to
the construction of this Agreement unless the construction is plainly contrary to the intent of the parties: 
  

	 	(i)	Where language has a generally prevailing meaning, it is interpreted in accord with that meaning; 

 

	 	(ii)	Technical terms and terms of art are given their technical meaning when used in a transaction within their technical field; 

 

	 	(iii)	Capitalized words and terms are as defined in the attached Exhibit A - Definitions or in the text of the main section of this Agreement, as the case may
be; 

  
 19 of 31

	 	(iv)	Singular words may be treated as plural and plural words may be treated as singular; and 

 

	 	(v)	Masculine gender words may be treated in the feminine and feminine gender words may be treated as masculine. 

(c) In computing any period of time under this Agreement, the day of the act, event, or default from which the designated period of time begins to run is
not included. The last day of the period so computed is included, unless it is a Saturday, a Sunday, or a Business Holiday. 
  

	34.	Choice of Law 

 This Agreement shall be
governed by and construed in accordance with the laws of New York, disregarding its conflict of laws principles which might otherwise require the application of the laws of another jurisdiction. The parties expressly exclude the United Nations
Convention on Contracts for the International Sale of Goods from this Agreement. 
  

	35.	Survival 

 The expiration, termination or
cancellation of this Agreement will not extinguish the rights of either party that accrue prior to expiration, termination or cancellation or any obligations that extend beyond termination, expiration or cancellation, either by their inherent nature
or by their express terms. 
  

	36.	Execution in Counterparts 

 This Agreement
may be executed in separate identical copies (counterparts), each of which is considered an original, but all of which, when taken together, are one Agreement. Delivery of an executed counterpart by Electronic or facsimile transmission is as
effective as delivery of an original written counterpart. 
  

	37.	No Waiver 

 (a) No provision of this
Agreement is waived unless the waiver is in writing and signed by an authorized representative of the party granting the waiver. 
 (b) No delay
in exercising any right, power or privilege under this Agreement will operate to waive completely or partially any present or future exercise of that right, power or privilege. 

 

	38.	Notice 

 (a) Unless specifically directed
otherwise in the Agreement, whenever written notice is required by this Agreement, it must be delivered to the attention of the individual indicated below by: 
  

	 	(i)	certified mail, postage pre-paid, return receipt requested; 

  

	 	(ii)	hand delivery; 

  

	 	(iii)	commercial overnight delivery service such as Federal Express or United Parcel Service; or 

 

	 	(iv)	facsimile. 

  
 20 of 31

 (b) Either party may change its address for notices by written notice to the other. 

(c) Notice is effective when received. If delivery of any written notice under this Agreement cannot be made despite the exercise of diligent efforts,
the requirement to give notice is excused. 
  

							
	If Xellia gives ViroPharma notice:
		
	Deliver notice to:	  	Send a copy to:
		
	 ViroPharma Incorporated
 730 Stockton Drive
 Exton, PA 19341
	  	 ViroPharma Incorporated
 730 Stockton Drive
 Exton, PA 19341

		
	Attention:         Director, Supply Chain	  	Attention:         General Counsel
		
	Facsimile:         (610) 458-7380	  	Facsimile:         (610) 458-7380
	
	If ViroPharma gives Xellia notice:
		
	Deliver notices to:	  	Send a copy to:
		
	 Xellia Pharmaceuticals ApS
 Dalslandsgade 11
 P.O. Box 1736
 2300 Copenhagen S, Denmark
	  	 Xellia Pharmaceuticals, Inc.
 34121 N. Hwy 45, Suite 207
 Grayslake, IL 60030 USA

USA

		
	Attention:         Legal Department	  	Attention:         Director of US Sales
		
	Facsimile:         +45 3264 5501	  	Facsimile:         +1-847-201-8468

 

	39.	Integrated Agreement and Amendments 

  

	Integrated	Agreement 

 (a) This Agreement (including
any documents referenced by it) is the final, complete and exclusive expression of all the statements, promised, terms and conditions within its scope. This Agreement supersedes all prior agreements or promises, whether written or oral, within its
scope, and shall not be modified except by an Amendment as described below in subsection 39(b). Notwithstanding the foregoing, this Agreement shall not be understood to supersede, amend or modify the letter agreement dated as of December 14,
2010 between the parties, which shall remain in full force and effect. Neither party has 

  
 21 of 31

 
relied upon any representation whatsoever by the other party, other than representations in this Agreement. No provision set forth in any Purchase Order, order confirmation form or any other
writing pertaining to an order placed under this Agreement which is inconsistent with or in addition to the provisions of this Agreement shall be binding on either party except as set forth in an Amendment. 

 

	Amendments	

 (b) No amendment to this Agreement will
be binding on either party unless it is in writing and signed by an authorized representative of each party. 

  
 22 of 31

 Agreed and accepted: 

 

			
	Xellia Pharmaceuticals Inc.	  	ViroPharma Incorporated
		
	Signed: /s/ Carl-Åke Carlsson            	  	Signed: /s/ Vincent J. Milano            
		
	Name: Carl-Åke Carlsson	  	Name: Vincent J. Milano
		
	Title: Chief Executive Officer	  	Title: President and Chief Executive Officer

  

			
	Exhibits:	  	 
	Exhibit A	  	Definitions
		
	Exhibit B	  	Quality Agreement
		
	Exhibit C	  	Product Specifications
		
	Exhibit D	  	Insurance
		
	Exhibit E	  	Shipping

  
 23 of 31

 EXHIBIT A: Definitions 
 An Affiliate of a party means any entity that controls, is controlled by, or is under common control with that party. One entity is deemed to control the other if and only if it directly or
indirectly (1) owns more than fifty percent (50%) of the equity in the other; or (ii) controls more than fifty percent (50%) of the voting rights of the other. 
 Agreement means the body of this Agreement and any exhibits and amendments to any of them. 

Xellia’s Confidential Information means information that ViroPharma receives from Xellia in performing under this Agreement that is
nonpublic, confidential, or proprietary in nature to Xellia and includes third party information that Xellia is obligated to maintain in confidence. The confidential nature of information is not affected by the manner of its communication to or
acquisition by ViroPharma, whether by oral, visual, written, Electronic or other means. Xellia’s Confidential Information does not include information that is excluded from the definition of Confidential Information under the provisions of
Section 20(b) in the main section of this Agreement. 
 Xellia’s Intellectual Capital means all Intellectual Property owned by
Xellia that was created, developed or reduced to practice prior to Xellia’s performance under this Agreement. 
 Xellia’s
Property means any Intellectual Property and other personal property, both tangible and intangible, owned solely or jointly by Xellia, whether such ownership arises under this Agreement or otherwise. 

Amended and Restated Quality Agreement means the document to be attached hereto as Exhibit B - Quality Agreement. 

 Applicable Law means any statute, law, treaty, rule, code, ordinance, regulation, permit, interpretation, certificate or order of a
Government Authority, or any judgment, decision, decree, injunction, writ, order, subpoena, or like action of any court, arbitrator or other government entity including the U.S. Federal Food, Drug & Cosmetic Act and the food, drug and
environmental laws in ***, as applicable. 
 Annual Reportable Changes means minor changes in the drug substance, drug product,
production process, quality controls, equipment, or facilities that have minimal potential to have an adverse effect on the identity, strength, quality, purity or potency of the drug product. Annual reportable changes are submitted in an annual
update. 
 Business Holiday means any day on which a party to this Agreement is not regularly scheduled to be open for business.

 Claim includes claims, demands, lawsuits, administrative proceedings or similar actions. 

The Effective Date is the first day the Agreement is in effect, and is specified on the first page of this Agreement. 

Electronic relates to technology having electrical, digital, magnetic, wireless, optical, electromagnetic, or similar capabilities. 

Employee means an officer, director, employee or temporary contract worker. 

  
 24 of 31

 The Expiration Date is the day the term of the Agreement expires if it is not cancelled or terminated
sooner. 
 Fault means any of the following: (1) any breach, whether by act or omission, of a covenant, representation or warranty
under this Agreement; (2) negligence or gross negligence; and (3) any willful, wanton, or intentional misconduct. 
 Force
Majeure is any cause that is beyond the party’s reasonable control, as more specifically defined in Section 29. 
 Government
Authority means any state, local or foreign government entity, authority, agency, instrumentality, court, tribunal, regulatory commission or other body, whether legislative, judicial, administrative or executive (or a combination or permutation
thereof), and any arbitrator to whom a dispute has been presented under government rule or by agreement of the parties with an interest in such dispute. 
 Indemnitee is a Person with a right to be indemnified. 
 Indemnitor is a Person with
an obligation to indemnify another Person. 
 Intellectual Property means all inventions, original expressions of ideas embodied in a
tangible form, trademarks, trade secrets, and the like that are afforded (or may be afforded upon action by a Government Authority, such as the United States or other country Patent Office or its equivalent agency) property rights (or quasi-property
rights) including patents, copyrights, trademarks, trade secrets, publicity rights, privacy rights, and moral rights (such as rights of attribution and integrity). 
 ViroPharma’s Confidential Information means information that Xellia receives from ViroPharma in performing this Agreement that is nonpublic, confidential, or proprietary in nature to
ViroPharma and includes third party information that ViroPharma is obligated to maintain in confidence. The confidential nature of information is not affected by the manner of its communication to or acquisition by Xellia, whether by oral, visual,
written, Electronic or other means. ViroPharma’s Information does not include information excluded from the definition of Confidential Information under the provisions of Section 20(b) in the main section of this Agreement. 

ViroPharma’s Property means any Intellectual Property and other personal property, both tangible and intangible, owned solely or jointly by
ViroPharma, whether such ownership arises under this Agreement or otherwise. 
 Loss includes losses, damages, liabilities, costs, or
expenses (including interest, penalties and, subject to the provisions in Section 28 (Indemnification), reasonable attorney fees, accounting fees, and expert witness fees) recoverable at law or in equity, whether sounding in contract, tort,
strict liability or other theory. 
 Minimum Yield means the minimum yield, if any, specified in the applicable Agreement. 

Person includes an individual, partnership, corporation and association. 
 Product means vancomycin HCL. 
 Product Specifications means the product
specifications identified in and attached to this Agreement as Exhibit C: Product Specifications.  

  
 25 of 31

 Quality Agreement means the document attached hereto as Exhibit B: Quality Agreement
and which sets out the parties respective responsibilities for Product quality. 
 Record means without limitation, all
information, data, text, images, sounds codes, source codes, computer programs, software, data bases or the like, used, created or obtained in the performance of this Agreement, inscribed in tangible medium or stored in and Electronic or other
medium and that is retrievable in perceivable form. 
 Subcontractor means any individual, partnership, corporation, association or other
entity that performs any of the obligations of Xellia under this Agreement, whether in privity to Xellia or in privity to another Subcontractor. 

  
 26 of 31

 EXHIBIT B: QUALITY AGREEMENT 
 See attached. 

  
 27 of 31

 EXHIBIT C: PRODUCT SPECIFICATIONS 
 Specification for Vancomycin HCl, USP 
  

					
	 Tests
	  	 Method
	  	 Acceptance Criteria

			
	***	  	***	  	***
			
	***	  	***	  	***
			
	***	  	***	  	***
			
	***	  	***	  	***
			
	***	  	***	  	***
			
	***	  	***	  	***
			
	***	  	***	  	***
			
	***	  	***	  	***
			
	***	  	***	  	***

  
 28 of 31

 EXHIBIT D: INSURANCE 

 

			
	 Policy
	  	 Limits

	General Liability	  	***
		
	Umbrella liability following from the above policies	  	***

  
 29 of 31

 EXHIBIT E: SHIPPING 

 

	 	•	 	 Xellia will book shipments with: 

 *** 
 or such other carrier as is identified by Xellia. 

 

	 	•	 	 Shipment Method: 

 Air
or Surface as specified 
  

	 	•	 	 Shipping conditions: (See Quality Agreement) 

  

	 	•	 	 Temperature monitoring: (See Quality Agreement) 

  

	 	•	 	 Ship to address: 

Specified on Purchase Order 
  

	 	•	 	 Shelf Life of API: 

Material should have *** or more shelf life prior to shipment. 
  

	 	•	 	 Shipment Documentation: 

Certificate of Analysis for each lot shipped and packing list will accompany each shipment. The Certificate of Analysis results displayed will be as
requested by ViroPharma. 
 (See Exhibit B for Quality Agreement) 
 Upon shipment, Xellia will fax the following documents to ViroPharma 
 Quality (***)]and
Supply Director (***) and CMC Director (***) 
 Certificate of Analysis for each lot shipped 

Commercial Invoice 
 Packing list 

 

	 	•	 	 Quality Control Release: (see Appendix for Quality Agreement) 

 

	 	•	 	 Receipt of Damaged Product: 

  
 30 of 31

 IAW Section 26 of Agreement 
 ViroPharma will file claims for lost and damaged product and transportation from Xellia to OSG Norwich (USA) 

  
 31 of 31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]